Concentrations of trovafloxacin in colonic tissue and peritoneal fluid after intravenous infusion of the prodrug alatrofloxacin in patients undergoing colorectal surgery

被引:8
作者
Melnik, G
Schwesinger, WH
Dogolo, LC
Teng, RL
Vincent, J
机构
[1] Univ Texas, Hlth Sci Ctr, San Antonio, TX 78284 USA
[2] Pfizer Inc, Pfizer Cent Res, Groton, CT 06340 USA
关键词
D O I
10.1016/S0002-9610(98)00214-1
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: Trovafloxacin is a new fourth-generation fluoroquinolone whose pharmacokinetics and in vitro activity suggest that it is well suited for antibiotic prophylaxis in elective colorectal surgery. Alatrofloxaccin is a prodrug that is rapidly hydrolyzed to trovafloxacin in the body. METHODS: Twelve patients received a single dose of alatrofloxacin equivalent to 200 mg trovafloxacin by intravenous infusion over 1 hour. Surgery was started at various time points relative to infusion time to allow determination of trovafloxacin concentrations in serum, colonic tissue, and peritoneal fluid as a function of time. RESULTS: The concentration in the earliest colonic tissue sample (1.4 hours after dosing) was 1.4 mu g/g. The maximum colonic tissue concentration was 2.8 mu g/g in a sample taken 2 hours after dosing. Colonic tissue/serum concentration ratios in samples taken 2-10 hours after the end of infusion ranged from 0.8 to 1.47. Concentrations of trovafloxacin in peritoneal fluid ranged from below the level of quantitation to 2.1 mu g/mL at the time of colonic tissue sampling and from below the level of quantitation to 2.5 mu g/mL at the time of wound closure. Alatrofloxacin was well tolerated. CONCLUSIONS: After a single intravenous dose of alatrofloxacin equivalent to 200 mg trovafloxacin, trovafloxacin is distributed rapidly into colonic tissue and peritoneal fluids. Tissue concentrations approximate serum concentrations and decline in parallel for up to 10 hours after dosing. (C) 1998 by Excerpta Medica, Inc.
引用
收藏
页码:14S / 17S
页数:4
相关论文
共 17 条
[1]  
BRIGGSGOODING B, 1993, ANTIMICROB AGENTS CH, V37, P349
[2]   The chemistry and biological profile of trovafloxacin [J].
Brighty, KE ;
Gootz, TD .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 :1-14
[3]   Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against Gram-positive cocci [J].
Coque, TM ;
Singh, KV ;
Murray, BE .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1996, 37 (05) :1011-1016
[4]   INVITRO ACTIVITY OF CP-99,219, A NEW FLUOROQUINOLONE, AGAINST CLINICAL ISOLATES OF GRAM-POSITIVE BACTERIA [J].
ELIOPOULOS, GM ;
KLIMM, K ;
ELIOPOULOS, CT ;
FERRARO, MJ ;
MOELLERING, RC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (02) :366-370
[5]   In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates [J].
Felmingham, D ;
Robbins, MJ ;
Ingley, K ;
Mathias, I ;
Bhogal, H ;
Leakey, A ;
Ridgway, GL ;
Gruneberg, RN .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 :43-49
[6]   In vitro activity and selection of disk content for disk diffusion susceptibility tests with trovafloxacin [J].
Fuchs, PC ;
Barry, AL ;
Brown, SD ;
Sewell, DL .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1996, 15 (08) :678-682
[7]   IN-VIVO EFFICACY OF TROVAFLOXACIN (CP-99,219), A NEW QUINOLONE WITH EXTENDED ACTIVITIES AGAINST GRAM-POSITIVE PATHOGENS, STREPTOCOCCUS-PNEUMONIAE, AND BACTEROIDES-FRAGILIS [J].
GIRARD, AE ;
GIRARD, D ;
GOOTZ, TD ;
FAIELLA, JA ;
CIMOCHOWSKI, CR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (10) :2210-2216
[8]   IN-VITRO ACTIVITY OF THE NEW FLUOROQUINOLONE CP-99,219 [J].
NEU, HC ;
CHIN, NX .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (11) :2615-2622
[9]   Surgical infections: Prevention and treatment - 1965 to 1995 [J].
Nichols, RL .
AMERICAN JOURNAL OF SURGERY, 1996, 172 (01) :68-74
[10]   Efficacy of trovafloxacin (CP-99,219), a new fluoroquinolone, in an animal model of intraabdominal sepsis [J].
Onderdonk, AB .
INFECTIOUS DISEASES IN CLINICAL PRACTICE, 1996, 5 :S117-S119